|
GlobalData analysts previously flagged Orzeyful’s approval as a key Q3 catalyst for the pharma industry due to the drug’s ‘transformative’ potential.
|
 |
|
Alongside Alkeus, several companies like Belite Bio, Ocugen and Nanoscope are aiming to secure a place on the Stargardt market where there are no approved therapies.
|
|
|
The biotech will now focus on the two other BiTEs in its pipeline, CTIM-76 and CT-202.
|
|
|
The partnership gives Ono the exclusive option to license worldwide rights to develop the therapeutic programmes.
|
|
|
The partnership intends to leverage complementary scientific strengths to boost early-stage research and produce new medicines.
|
|
